It seems that in subjects without concomitant endocrine disorders, HMG-CoA reductase inhibitor-induced impairment in cellular glucose intake [26] is counterbalanced by anti-inflammatory properties of statins [27]. The gene discussed is HMGCR; the disease is endocrine system disorder.